The EPS projection of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for period quarter closed 2016-12-31 is $0.33.
The EPS estimates given 30-days and 1 week ago were $0.33 and $0.33, correspondingly. This number 90 and 60 days before was $0.33 and $0.33 respectively. Yet, from last week, the change in EPS prediction is 0%.
For the quarter ended 2 mean estimate is $0.33 based on 2 EPS estimations. As on 2016-08-03 estimated EPS was $0.23 showing surprise of $0.02, or 9.52%. Following the given predictions, the standard deviation is $0.01.
The upgrade count for EPS revisions was 0 a week earlier paralleled to negative revisions of 0. In last 60-days and 1- month, the upgrade in EPS reviews were 0 and 0 correspondingly, though for a quarter and 120-days ago, it was 1 and 1 in that sequence.
The negative reviews of EPS in the last 60-days and 1-month were 0 and 0 in that order. But, a quarter and 120-days ago, this numeral was 1 and 1 correspondingly.
EPS reviews downgrade and upgrade for last 18 days were 1 and 1, correspondingly.
Quarterly Sales Estimates
The mathematical mean of apparent yearly sales of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is $56.982 and the median is $55.65. The estimate is stated by 4 analysts for the fiscal 2016.
The highest yearly projection is $61.728 and lowest sales mark is $54.9. This results a standard deviation of $3.183.
Almost 4 have reviewed sales target for better in the past week and 4 have downgraded forecasts. Subject to the stated estimates, the intended change in disclosed target from the past week is 0%.
Nearly 4 revised sales predictions for better over the past month and 4 have downgraded forecasts. It suggests an average deviation of 0% across given estimates.
Just about 4 have revised sales forecast up over the quarter and 4 have downgraded forecasts, hinting to a deviation of -3.42%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...